Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342179 | 1.00 | HTT (0.43) | HTTPPARAPPARDCETPAKR1C3 | |
| SCHEMBL14387510 | 0.83 | KDR (0.49) | HTTRXFP1 | |
| SCHEMBL6937344 | 0.77 | SLC6A1 (0.44) | — | |
| SCHEMBL6937348 | 0.77 | SLC6A1 (0.44) | — | |
| SCHEMBL5342361 | 0.76 | MAPT (0.54) | HTT | |
| SCHEMBL23393372 | 0.76 | HTT (0.49) | HTT | |
| SCHEMBL23393374 | 0.76 | HTT (0.49) | HTT | |
| SCHEMBL30070797 | 0.74 | HTT (0.50) | HTTRXFP1 | |
| SCHEMBL21483581 | 0.74 | HTT (0.50) | HTTRXFP1 | |
| SCHEMBL6934974 | 0.72 | NPSR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291648-B2 | 3,3-diphenylpropylamines useful in therapy | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060281812-A1 | NOVEL 3,3-diphenylpropylamines USEFUL IN THERAPY | PHARMACIA & UPJOHN COMPANY LLC | 2006-12-14 | — | — | US | disclosed |
| US-7119121-B2 | 3,3-diphenylpropylamines useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1620389-A1 | HALOGEN SUBSTITUTED 3,3-DIPHENYLPROPYLAMINES (TOLTERODINE) HAVING ANTIMUSCARINIC ACTIVITY | Pharmacia & Upjohn Company LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20060004106-A1 | Novel 3,3-diphenylpropylamines useful in therapy | PFIZER INC | 2006-01-05 | — | — | US | disclosed |
| US-20050004223-A1 | Novel 3,3-diphenylpropylamines useful in therapy | PFIZER INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004096751-A1 | HALOGEN SUBSTITUTED 3,3-DIPHENYLPROPYLAMINES (TOLTERODINE) HAVING ANTIMUSCARINIC ACTIVITY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281812-A1 | NOVEL 3,3-diphenylpropylamines USEFUL IN THERAPY | QDPR, HRH3, SLC7A1 | HTT 1535/4885PPARA 1873/4885PPARD 2474/4885 |
| US-20060004106-A1 | Novel 3,3-diphenylpropylamines useful in therapy | QDPR, HRH3, SLC7A1 | HTT 1535/4885PPARA 1873/4885PPARD 2474/4885 |
| US-20050004223-A1 | Novel 3,3-diphenylpropylamines useful in therapy | CHRM2, CHRM3, HRH3 | HTT 2798/4885PPARA 1558/4885PPARD 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.